Year: 2014

Protein Structure Initiative Transition Planning Committees

0 comments

Shortly after NIGMS Director Jon Lorsch announced plans to sunset the Protein Structure Initiative after the completion of the PSI:Biology phase in 2015, he commissioned two committees to determine what unique resources and capabilities developed during the PSI should be preserved and how that should be done. The committees, which are working together, held their first meetings in December and expect to present their recommendations within the year.

The external committee, which includes practitioners of structural biology and biomedical researchers who use structural biology data and resources in their work, will primarily focus on community needs. It also will suggest emerging challenges and opportunities in structural biology.

The internal committee, which is composed of NIH staff, will focus on how to implement the priorities identified by the external committee. The group includes a member from each NIGMS scientific division as well as several representatives from other NIH institutes who have experience managing structural biology and large, complex research programs.

The work of these committees will help define how we can provide continued access to important structural biology resources and identify new directions for technology development with potential for broad biomedical impact.

As Jon wrote in a Feedback Loop post about bolstering support for investigator-initiated research and as also reported in a Nature news article, the decision to sunset a large set-aside program that has received substantial investments, such as the PSI, should not be interpreted as a lack of support for team science. Multidisciplinary collaborations are likely to become increasingly important as we delve deeper into complex biological problems, and we will continue to sponsor team approaches to biomedical research. We also remain committed to supporting structural biology research through investigator-initiated grant mechanisms, innovative technology development and access to critical resources.

Our Investigator-Initiated SBIR/STTR Program

0 comments

In January, NIH and several other agencies issued new omnibus solicitations for the Small Business Innovation Research (PA-14-071) and Small Business Technology Transfer (PA-14-072) programs. A program descriptions and research topics document gives details about each funding component’s areas of interest. The NIGMS section begins on page 91.

Potential SBIR/STTR applicants often assume that, like some other federal agencies, NIGMS will be an end user of the tools, devices, products or services being created under the grant or will play an active role in their ongoing development toward eventual commercialization. As a result, we get questions like:

  • How can I ensure that my project offers what NIGMS needs?
  • Can NIGMS provide technical and/or regulatory assistance to help my project obtain FDA approval?
  • What clinical trial/technology development expertise does NIGMS have that I may access?

These assumptions are not correct. Like the vast majority of NIGMS-funded research, our SBIR/STTR program is investigator-initiated. Applicants propose what to do, how to do it and the best path toward commercialization. Although we may occasionally issue or participate in SBIR/STTR funding opportunity announcements targeted to stimulate activity in a specific area, these are still independent projects because we do not prescribe what the activity should be or how it should be pursued.

Our goal is to support innovative SBIR/STTR projects that could benefit the broader research and development communities and/or directly impact human health.

If you’re interested in applying for an SBIR/STTR grant in an NIGMS area of interest, you can get general advice and answers to many procedural and technical questions about the application and review process from NIGMS program and grants management staff. If you don’t know whom to contact, you can start by asking me your program questions or asking Patrice Molnar your grants management questions. If we don’t know the answers ourselves, we can refer you to others as appropriate.

You can also find useful information on the NIH SBIR/STTR Web site and in a recent blog post from NIH’s Sally Rockey titled What’s New with NIH’s Small Business Research Programs?

Funding Trends and Factors Affecting Success Rate

4 comments

On January 17, the President signed into law the Consolidated Appropriations Act of 2014, funding the Federal Government for the remainder of the fiscal year and providing increased support for NIH relative to the post-sequester levels of 2013. The NIGMS Fiscal Year 2014 budget is $2.359 billion, which is about $66 million, or 2.9%, higher than it was in Fiscal Year 2013.

It’s too early to know what this will mean for the NIGMS grant application success rate—the number of competing R01 applications we fund divided by the total number of competing R01 applications we receive. A number of other, largely independent factors in addition to the budget can impact the success rate, as well. We hope that our latest analysis of NIGMS funding trends illuminates the interplay among some of these factors. Thanks to Tony Moore, Jim Deatherage and Ching-Yi Shieh for help with the data collection and analysis.

Figure 1 shows the percentage of R01 applications funded by NIGMS as a function of percentile scores for Fiscal Years 2009-2013. Fewer grants scoring above about the 12th percentile were funded last year than in the previous 4 years. In fact, the funding curves shifted more to the left each year in this period, except in 2012, which had a slightly better success rate than 2011. This was due in part to a dip in noncompeting R01 grants that had to be funded along with no increase in the number of competing applications relative to 2011. (For a 4-year R01, the second, third and fourth years are all noncompeting grants because they are funded without review by a study section. The funds required to pay the noncompeting awards are often referred to as “out-year commitments.”) Funding levels fell again in Fiscal Year 2013 due to the sequester cuts and increases in the numbers of competing applications and noncompeting grants (see below).

Figure 1. Percentage of competing R01 applications funded by NIGMS as a function of percentile scores for Fiscal Years 2009-2013. For Fiscal Year 2013, the success rate for R01 applications was 21%, and the midpoint of the funding curve was at approximately the 17th percentile. See more details about Figure 1 analysis.

Figure 2 presents a more granular view of the data for Fiscal Year 2013. The solid black bars correspond to the number of NIGMS competing R01 applications that scored at each percentile. The striped red bars show the number of these applications that we funded.

Figure 2. Number of competing R01 applications (solid black bars) assigned to NIGMS and number funded (striped red bars) in Fiscal Year 2013 as a function of percentile scores. See more details about Figure 2 analysis.

Figure 3 shows the success rate for Fiscal Years 2000-2013 (green line with triangles; right axis), the total number of NIGMS R01 applications each year (blue line with diamonds) and the number of funded competing R01 grants (red line with squares, left axis). Between Fiscal Years 2000 and 2003, the last year of the NIH budget doubling, the success rate was 37-38%. After the budget doubling ended, the success rate declined, falling to 26% in 2006. In 2007, the success rate jumped to 33%, largely due to a combination of a budget increase for NIH and a dip in the number of noncompeting grants NIGMS had to fund that year. (See below for more about changes in the number of noncompeting grants.) Over the next 6 years, the success rate for R01s dropped to 21%, the lowest level in two decades. Note that the Fiscal Year 2013 success rate for all research project grants (RPGs), which include R00s, R01s, R15s, R21s, R37s, P01s, DP1s, DP2s and U01s, was 19.9%. This is lower than the success rate for R01s alone, which was 21%.

Figure 3. Number of competing R01 applications assigned to NIGMS (blue line with diamonds, left axis) and number funded (red line with squares, left axis) for Fiscal Years 2000-2013. The success rate is shown in the green line with triangles (right axis).

One reason the success rate has fallen is that the number of applications increased between Fiscal Years 2002-2005 and then again between Fiscal Years 2010-2013. Similar trends are seen NIH-wide and are the result of a 50% increase in the number of investigators applying for grants along with a smaller increase in the average number of applications submitted per investigator.

Another factor that influences the success rate is the number of noncompeting awards. The more noncompeting awards we need to make in a given year, the fewer competing grants we can fund. The number of noncompeting RPGs cycles with a 4-year period, as shown in Figure 4.

Figure 4. Number of noncompeting (blue line with diamonds, left axis) and competing (red line with squares, right axis) RPGs funded by NIGMS for Fiscal Years 2000-2013. Note that the Y axes do not start at 0.

This cycle was apparently set in the early 1990s when the Institute shifted the duration of most competing RPGs from 5 to 4 years. The result was that the last group of 5-year awards and the first group of 4-year awards ended in the same year, creating a significant dip in noncompeting grants and a corresponding jump in competing grants that the Institute could fund. The bolus of grants awarded that year kept noncompeting commitments high for the next 3 years, until they all came up for renewal again. As you can see in Figure 4, the cycle has persisted to this day.

The cycle may lead you to wonder if you should try to time your application to correspond to a trough in noncompeting grants. You might get lucky and have all of the factors that drive success rate work in your favor. However, if other factors act to decrease the success rate, you might end up worse off. For example, even though 2011 was a trough year for noncompeting grants (Figure 4, blue line with diamonds), a jump in the number of applications (Figure 3, blue line with diamonds) worked in the opposite direction, and the success rate actually fell (Figure 3, green line with triangles).

Finally, the Institute’s budget is also a factor in determining the success rate. Figure 5 shows the NIGMS budget (red line with squares, left axis), the budget committed to competing and noncompeting RPGs (blue line with diamonds, left axis) and the ratio of the RPG budget to the total NIGMS budget (green line with triangles, right axis).

Figure 5. Total NIGMS budget (red line with squares, left axis) and budget committed to competing and noncompeting RPGs (blue line with diamonds, left axis) for Fiscal Years 2000-2013. The green line with triangles shows the ratio of the RPG budget to the total NIGMS budget (right axis). The jump in the NIGMS budget and corresponding drop in the RPG/NIGMS budget ratio occurred when large, primarily non-RPG programs were transferred to NIGMS along with their associated funds from the former National Center for Research Resources.

The Institute’s budget grew during the NIH budget doubling (1998-2003). It also jumped by nearly $400 million when the Institutional Development Award (IDeA) and Biotechnology Research Resources programs moved from the former National Center for Research Resources to NIGMS. A variety of pressures were responsible for the ~2% decline in the ratio of RPG funds to the NIGMS budget that occurred during Fiscal Years 2005-2011, including commitments to targeted initiatives and increased funding for training programs.

Because we don’t yet know the number of applications we will receive or the number of noncompeting grants that will end early due to retirements or other events, we can’t predict what our success rate will be in Fiscal Year 2014. We hope, however, that the steps we are taking to bolster our commitment to investigator-initiated RPGs will have a positive impact on the success rate.

Give Input on Training Activities Relevant to Data Reproducibility

2 comments

Data reproducibility is getting a lot of attention in the scientific community, and NIH is among those seeking to address the issue Link to external web site. At NIGMS, one area we’re focusing on is the needs and opportunities for training in areas relevant to improving data reproducibility in biomedical research. We just issued a request for information to gather input on activities that already exist or are planned as well as on crucial needs that an NIGMS program should address.

I strongly encourage you and your colleagues to submit comments by the February 28 deadline (no longer available). The information will assist us in shaping a program of small grants to support the design and development of exportable training modules tailored for graduate students, postdoctoral students and beginning investigators.

UPDATE: NIGMS and additional NIH components have issued the Training Modules to Enhance Data Reproducibility (R25) funding opportunity announcement. The application deadline is November 20.

Biomedical Technology Research Resources: Funding and Access Opportunities

0 comments

Our Biomedical Technology Research Resources (BTRRs)—until recently known as Biomedical Technology Research Centers—develop and disseminate cutting-edge technologies and methods that allow scientists nationwide to advance their projects beyond the levels that could be attained using commonly available laboratory resources.

If you’re a researcher who works collaboratively to create and integrate potentially transformative biomedical technologies and are interested in providing service and training to the scientific community, you may want to apply for a BTRR grant. The first step is to submit your concept in a pre-application. Feedback from its review can help you decide whether to submit a full application.

If you’re a biomedical researcher with a project in need of technology resources, you may be able to access them at an existing BTRR. The Biomedical Technology Resources Portal includes descriptions of the available resources, including those funded through NIH’s National Institute of Biomedical Imaging and Bioengineering, and instructions for accessing them.

Before granting use of its technologies (whether remotely or in-person), the BTRR will evaluate your research project for demonstrated need as well as the level of engagement and assistance that would be required of resource staff. It’s also possible that, if your project has potential for advancing a newly emerging technology, you’ll be able to collaborate with BTRR investigators as they develop it. This close collaboration benefits your research and also furthers innovation at the BTRR.

For more details about the BTRR program, please contact me or Doug Sheeley.

Web Chat to Stimulate Student Interest in Cell Biology and Research Careers

0 comments

Cell Day 2014: Web Chat with NIH Scientists. February 28, 2014. 10a.m. to 3 p.m. ESTWe’re hosting another Cell Day interactive Web chat on Friday, February 28, from 10 a.m. to 3 p.m. EST. During this time, members of the NIGMS scientific staff, including our director Jon Lorsch, will answer questions from students, teachers and the public about cell biology and research careers.

You can follow the chat live from the Cell Day Web site or read the transcript, which will be posted there shortly after the event. The site also includes registration information, the transcript from the 2012 event and classroom resources about the cell.

Please let people in your local schools and community know about Cell Day.

This event is just one example of the Institute’s commitment to encouraging and preparing future generations of scientists via formal research training and informal learning opportunities.

Encouraging Model Organism Research

0 comments

Image of a planerian from the lab of Dr.  Alejandro Sánchez  Alvarado. Nervous system in green and photoreceptors in red. Image credit: Sarah Elliot and Lisandro Maya-RamosA recent article in NIH’s Peer Review Notes illustrated how Alejandro Sánchez Alvarado developed the planarian as a model organism for studying regeneration.

When he applied for his first NIH grant in 1997, Sánchez Alvarado was a new investigator at the Carnegie Institution of Washington who had little preliminary data supporting his proposal. The peer reviewers astutely recognized the promise of his grant application, and they scored it favorably.

NIGMS funded the grant and continues to support Sánchez Alvarado’s studies, now at the Stowers Institute for Medical Research. Since receiving that first grant, Sánchez Alvarado has helped turn planaria into tiny workhorses that have opened new avenues for understanding tissue regeneration and other developmental processes. He has also trained and mentored graduate students and postdocs and served the scientific community as a study section and NIGMS advisory council member.

Sánchez Alvarado’s work is just one example of how NIGMS-funded research on model organisms, including those that are currently considered unconventional, has significantly advanced scientific progress. Think of the protozoan Tetrahymena thermophila and the discovery of telomeres, or the nematode Caenorhabditis elegans and the discovery of RNA interference. The fungus Neurospora crassa has been an important player in understanding the genetics of circadian rhythms, and the bacterium Caulobacter crescentus has led to important insights on the regulation of cell division.

We have long supported research using these and many more model organisms, including mammalian species and other vertebrates, invertebrates, plants, yeast, and additional bacteria. We know that findings made in such systems can translate rapidly—and often unexpectedly—into leaps in conceptual understanding of fundamental life processes, the development of better research tools and approaches, and new strategies for diagnosing and treating diseases. We also know that we can never predict where the next breakthrough will come from—or in which organism. So we continue to encourage applications for projects that use model organisms, including uncommon ones, when these systems offer distinct scientific advantages.

NIGMS Training, Workforce Development, and Diversity Division Director Clif Poodry Retires

23 comments

Clifton Poodry, Ph.D.Clifton “Clif” Poodry, Ph.D., director of the NIGMS Division of Training, Workforce Development, and Diversity, retired earlier this month. Although he’s left federal service, Clif is continuing to pursue his long-held interest in improving science education as a senior fellow at the Howard Hughes Medical Institute.

Throughout his nearly 20 years at NIGMS, Clif championed—and in many cases, led—activities to build the biomedical research workforce of the future. This included initiatives for training and mentoring students from groups that are underrepresented in biomedical and behavioral research and advising on NIH-wide programs, such as the newly announced Building Infrastructure Leading to Diversity program.

Clif has long been committed to using scientific approaches to understand interventions that promote interest in and pursuit of research careers. He consistently encouraged staff and colleagues to read the scientific literature on training and workforce diversity in order to develop a better understanding of biomedical workforce issues and challenges so that we could create and/or modify programs accordingly.

Clif’s long and distinguished career includes time as a biology professor, department chair, associate vice-chancellor for student affairs, and NIGMS grantee at the University of California, Santa Cruz. In the early 1980s, he served a 2-year stint at the National Science Foundation, where he helped create a program that later became a model for the NIH diversity supplement program.

Clif is a great and natural mentor who has touched the lives of numerous students and colleagues across the country, as well as those of us here at NIGMS and NIH. Many of those he mentored have gone on to positions in academia, government and the private sector.

Clif has had a huge impact in many areas, including the education and training of students from underrepresented groups, and we look forward to building on his legacy.

Funding Opportunities: NIH Big Data to Knowledge, Research Centers for Pharmacogenomics in Precision Medicine

0 comments

You may be interested in these recent funding opportunity announcements:

NIH Big Data to Knowledge (BD2K)

NIGMS is participating in additional BD2K programs, an NIH-wide initiative that enables the biomedical research community to use various types of big data for research:

  • Development of an NIH BD2K Data Discovery Index Coordination Consortium (U24)
    (RFA-HL-14-031)
  • BD2K-LINCS-Perturbation Data Coordination and Integration Center (U54)
    (RFA-HG-14-001)
  • Mentored Career Development Award in Biomedical Big Data Science for Clinicians and Doctorally Prepared Scientists (K01)
    (RFA-HG-14-007)
  • Courses for Skills Development in Biomedical Big Data Science (R25)
    (RFA-HG-14-008)
  • Open Educational Resources for Biomedical Big Data (R25)
    (RFA-HG-14-009)

Research Centers for Pharmacogenomics in Precision Medicine (P50)
(PAR-14-075)

Purpose: This program will support a limited number of large-scale centers to conduct cutting-edge research studies designed to push the boundaries for understanding and predicting therapeutic drug responses.
Letters of intent due date: 30 days before the application due dates
Application due dates: September 25, 2014; September 25, 2015; and September 25, 2016.
NIGMS contact: Rochelle Long, 301-594-3827.

Advisory Council Meeting: Attend, Watch, Comment

0 comments

The National Advisory General Medical Sciences Council will have its winter meeting on January 23-24, 2014. Although the first day is a closed session for the review and discussion of grant applications, Friday’s portion of the meeting is open to the public. The agenda includes presentations on NIGMS programs and policy changes as well as a public comment period.

You may attend the open session in person or watch the presentations and discussions live or later.